Skip to main content
Simcere Pharmaceutical Group Limited logo

Simcere Pharmaceutical Group Limited — Investor Relations & Filings

Ticker · S2P ISIN · HK0000658531 HKEX Manufacturing
Open in API
Filings indexed 577 across all filing types
Latest filing 2022-12-18 Regulatory Filings
Country CN China
Listing HKEX S2P

About Simcere Pharmaceutical Group Limited

https://www.simcere.com/en/

Simcere Pharmaceutical Group Limited is an R&D-driven pharmaceutical company specializing in the discovery, development, and commercialization of innovative and branded generic prescription drugs. The company strategically focuses on core therapeutic areas, including neuroscience, anti-oncology, and inflammatory diseases. Simcere emphasizes synergistic innovation, evidenced by its development and launch of multiple Category I innovative pharmaceuticals and its strategic collaborations with global partners to advance novel treatments. These partnerships aim to address significant unmet medical needs and expand the company's portfolio across specialized disease areas.

Recent filings

Filing Released Lang Actions
VOLUNTARY ANNOUNCEMENT - A PHASE II/III CLINICAL STUDY OF ANTI-SARS-COV-2 DRUG CANDIDATE XIANNUOXIN (SIM0417) COMPLETE ALL PATIENTS ENROLLMENT
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by Simcere Pharmaceutical Group Limited regarding the completion of patient enrollment in a Phase II/III clinical study for an anti-SARS-CoV-2 drug candidate. It provides detailed information about the study, the drug, and the involved research institutes. The document is not a financial report, earnings release, or regulatory filing related to financial performance. It is a business update announcement about clinical trial progress, which does not fit into categories like Annual Report, Interim Report, or Earnings Release. It is also not a regulatory filing or certification. Given the nature of the content and the fact it is a voluntary announcement informing shareholders and investors about a significant business development, the best fitting category is Regulatory Filings (RNS), which serves as a fallback for miscellaneous announcements that do not fit other specific categories. The document length (6456 characters) and content confirm it is a full announcement rather than a brief notice or report publication announcement.
2022-12-18 English
DELAY IN DESPATCH OF CIRCULAR IN RELATION TO THE PROPOSED GRANT OF RSUS TO THE CONNECTED GRANTEES UNDER THE 2021 RSU SCHEME
Regulatory Filings Classification · 95% confidence The document is an announcement from Simcere Pharmaceutical Group Limited regarding a delay in the despatch of a circular related to the proposed grant of restricted stock units (RSUs) under a 2021 RSU scheme. It references a previous announcement and states that the circular, which includes details of the proposed RSU grants and related advice, will be sent out later than originally planned. The document is short (2344 characters) and does not contain any financial statements or substantive financial data. It is clearly an announcement about the timing of a report (the circular) rather than the report itself. Therefore, it fits the criteria for a Regulatory Filing (RNS) as a general regulatory announcement that does not fit into more specific categories.
2022-12-09 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 November 2022
Regulatory Filings Classification · 95% confidence The document is a monthly return report detailing movements in issued shares of Simcere Pharmaceutical Group Limited, including share capital changes, share options, and other share issuances. It is addressed to the Hong Kong Exchanges and Clearing Limited and follows the format of a regulatory submission under the Exchange Listing Rules. The document does not contain financial statements or management discussion but focuses on share capital movements and confirmations related to securities. This type of document is a regulatory filing related to share capital movements and does not fit into categories like Annual Report, Earnings Release, or Capital/Financing Update. It is not a report publication announcement since it contains substantive data. The best fitting category is Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements and compliance documents that do not fit other specific categories.
2022-12-05 English
VOLUNTARY ANNOUNCEMENT - PHASE III CLINICAL STUDY OF SANBEXIN SUBLINGUAL TABLETS FOR THE TREATMENT OF ACUTE ISCHEMIC STROKE ACHIEVED EXPECTED EFFICACY ENDPOINTS
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by Simcere Pharmaceutical Group Limited regarding the successful completion and preliminary positive results of a Phase III clinical study for a drug treatment. It is an update on business development and clinical trial progress, not a financial report, regulatory filing, or management report. The document is relatively short (5299 characters) and serves as a public announcement of clinical trial results rather than a detailed report or presentation. It does not contain financial data, voting results, or management changes. Therefore, it fits best into the category of a Regulatory Filing (RNS) as a general announcement that does not fit other specific categories.
2022-12-01 English
VOLUNTARY ANNOUNCEMENT - EXCLUSIVE LICENSE AGREEMENT WITH IDORSIA FOR THE INSOMNIA DRUG DARIDOREXANT
Capital/Financing Update Classification · 95% confidence The document is a voluntary announcement by Simcere Pharmaceutical Group Limited regarding an exclusive license agreement with Idorsia for a drug. It details the business development, terms of the agreement, and background information about the drug, Idorsia, and the company. There are no financial statements, regulatory filings, or meeting materials. The content is a business update about a licensing deal, which fits the category of a Capital/Financing Update (CAP) as it relates to a significant business transaction involving licensing and potential future payments and royalties. The document length is moderate and contains substantive information about the transaction, not just a brief notice or report publication announcement.
2022-11-16 English
(1) PROPOSED APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR&#x3b; (2) CHANGE OF JOINT COMPANY SECRETARY AND AUTHORIZED REPRESENTATIVE&#x3b; AND (3) WAIVER FROM STRICT COMPLIANCE WITH RULES 3.28 AND
Board/Management Information Classification · 100% confidence The document is an announcement from Simcere Pharmaceutical Group Limited regarding corporate governance changes: the proposed appointment of an independent non-executive director, changes in joint company secretary and authorized representatives, and a waiver from strict compliance with certain listing rules. It includes detailed biographical information about the new appointees and explanations about the waiver granted by the Stock Exchange. There are no financial statements or financial performance data presented. The content focuses on board and management changes and compliance with listing rules. Therefore, this document fits the category of Board/Management Information (MANG). The document length is substantial and contains detailed information about management changes, not just a brief announcement or a report publication notice.
2022-11-09 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.